Systemic vulnerabilities in global pharma supply chains highlight overreliance on China’s manufacturing dominance
Original framing: “Fears grow over US drug supply’s rising dependence on Chinese ingredients” — South China Morning Post
The piece references long-term trends in offshoring and trade liberalization, linking current vulnerabilities to historical patterns of industrial policy and globalization. It draws parallels between China’s industrial strategy and U.S. policy gaps, offering a historical lens on systemic underinvestment.
The article reveals a systemic overreliance on Chinese pharmaceutical manufacturing driven by decades of cost-driven globalization and underinvestment in domestic alternatives.
By examining historical patterns and cross-cultural industrial strategies, it exposes the fragility of a supply chain shaped by short-term economic logic. The lack of Indigenous and marginalized perspectives highlights a broader exclusion of alternative health paradigms. While the scientific and future-modelling dimensions are underdeveloped, the piece invites a rethinking of industrial policy through a lens of resilience and sovereignty. A trickster reading reveals the absurdity of a system that claims to prioritize health security while enabling dangerous dependencies. Systemic solutions must include diversification, domestic investment, and the integration of diverse knowledge systems to build a more equitable and resilient global health infrastructure.